Late clinical-stage biopharmaceutical company Vistagen Therapeutics Inc. (VTGN) faces a decisive period as it approaches key Phase 3 readouts for fasedienol, its intranasal candidate for social anxiety disorder.
Topline results from the PALISADE-3 Phase 3 trial of fasedienol, its intranasal candidate for the acute treatment of social anxiety disorder, are expected in the fourth quarter of 2025. A second late-stage study, PALISADE-4, is on track to deliver topline data in the first half of 2026.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.